NASDAQ:HOOKHookipa Pharma Stock Price, Forecast & News

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HOOK stock has increased by 18.3% and is now trading at $10.94.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Hookipa Pharma.

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Hookipa Pharma.

Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $3.70 million for the quarter, compared to analysts' expectations of $4.36 million. Hookipa Pharma had a negative return on equity of 36.53% and a negative net margin of 333.02%.
View Hookipa Pharma's earnings history.

2 equities research analysts have issued 1-year price targets for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 73.7% from the stock's current price.
View analysts' price targets for Hookipa Pharma.

News coverage about HOOK stock has trended extremely negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hookipa Pharma earned a coverage optimism score of -4.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
View the latest news about Hookipa Pharma.

Hookipa Pharma saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 180,700 shares, a drop of 10.5% from the April 30th total of 202,000 shares. Based on an average daily volume of 80,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 1.6% of the shares of the company are sold short.
View Hookipa Pharma's Short Interest.

Some companies that are related to Hookipa Pharma include Athenex (ATNX), Retrophin (RTRX), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Generation Bio (GBIO), Legend Biotech (PLRX), Aimmune Therapeutics (AIMT), Gossamer Bio (GOSS), BioXcel Therapeutics (BTAI), VBI Vaccines (VBIV), Repare Therapeutics (RPTX), Morphic (MORF), Omeros (OMER), Rhythm Pharmaceuticals (RYTM) and DiaMedica Therapeutics (DMCAF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Alector (ALEC), LogicBio Therapeutics (LOGC), Atreca (BCEL), Stoke Therapeutics (STOK), Tcr2 Therapeutics (TCRR) and Precision BioSciences (DTIL).

(HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Hookipa Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.15%), California Public Employees Retirement System (0.14%), New York State Common Retirement Fund (0.06%), First Trust Advisors LP (0.06%), American International Group Inc. (0.03%) and UBS Group AG (0.02%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr.
View institutional ownership trends for Hookipa Pharma.

HOOK stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Bank of New York Mellon Corp. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky, Klaus Orlinger, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma.

HOOK stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, New York State Common Retirement Fund, American International Group Inc., and First Trust Advisors LP. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma.

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HOOK stock can currently be purchased for approximately $10.94.

Hookipa Pharma has a market capitalization of $238.77 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Hookipa Pharma employs 56 workers across the globe.

The official website for Hookipa Pharma is www.hookipapharma.com.

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]